Matinas BioPharma Holdings, Inc.
MTNB
$0.59
-$0.05-7.84%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 77.33% | 64.16% | 8.29% | 71.57% | -58.69% |
| Total Depreciation and Amortization | -61.54% | -54.51% | -49.38% | -46.67% | 2.92% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -88.43% | -73.86% | 268.62% | -97.89% | 255.81% |
| Change in Net Operating Assets | -359.30% | 29.98% | -133.92% | 58.26% | 110.82% |
| Cash from Operations | 57.01% | 57.89% | 34.93% | 65.21% | 23.35% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -83.11% |
| Cash from Investing | -97.00% | -96.68% | -- | -- | -83.11% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -600.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 5,900.00% | 195.52% | -82.35% | 3,007.55% | 0.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 52.31% | -117.93% | -112.69% | 90.31% | -85.86% |